Canadian Institutes of Health Research Ethics Board

Canadian Institutes of Health Research Ethics Board is the centralized ethical review body associated with the Canadian Institutes of Health Research that provides oversight for biomedical and health research involving human participants. It operates within the context of federal policy frameworks such as the Tri-Council Policy Statement and engages with provincial bodies including Health Canada, Ontario Ministry of Health, and research institutions like the University of Toronto and the Montreal Heart Institute. The board interacts with international counterparts such as the National Institutes of Health, the European Commission, and the World Health Organization on harmonizing standards.

History

The board emerged amid debates following events like the Tuskegee syphilis study and regulatory developments such as the Nuremberg Code and the Declaration of Helsinki, paralleling reforms in bodies like the National Research Council and the Royal Society of Canada. Early influences included advisory reports from the Royal Commission on Health Services and policy shifts associated with leaders from the Canadian Medical Association and the Canadian Nurses Association. The formative period overlapped with institutional changes at the Public Health Agency of Canada and legislative initiatives influenced by cases in the Supreme Court of Canada and inquiries similar to the Krever Commission.

Mandate and Functions

The board's mandate aligns with obligations under the Tri-Council Policy Statement and cooperates with agencies such as CIHR Institute of Infection and Immunity, CIHR Institute of Population and Public Health, and departments like Indigenous Services Canada to ensure compliance with standards established by the Canadian Human Rights Tribunal and frameworks championed by organizations such as UNESCO and the Council of Europe. Its functions include ethics review of protocols submitted by researchers affiliated with institutions like McGill University, McMaster University, and University of British Columbia, advising on consent procedures relevant to populations represented by the Assembly of First Nations and the Inuit Tapiriit Kanatami, and contributing to policy development with stakeholders like Genome Canada, Canadian Blood Services, and the Royal College of Physicians and Surgeons of Canada.

Structure and Membership

Membership draws from sectors represented by entities such as Health Canada, the Public Health Agency of Canada, academic centres including the University of Alberta and Dalhousie University, and professional associations like the Canadian Psychological Association and the Canadian Pharmacists Association. The board includes chairs and members with backgrounds connected to institutions such as SickKids, St. Michael's Hospital, and the BC Children's Hospital, and liaises with provincial research ethics boards such as those at Sunnybrook Health Sciences Centre and Montreal General Hospital. Governance models reference practices from committees including the U.S. Food and Drug Administration's advisory panels and ethics frameworks akin to those used by the European Medicines Agency.

Review Processes and Policies

Review procedures reflect standards codified in documents from the Tri-Council Policy Statement, aligning with privacy principles articulated by the Office of the Privacy Commissioner of Canada and regulatory guidance from Health Canada and the Canadian Institutes of Health Research leadership. Protocol review incorporates input on data sharing with partners like CIHR Institute of Genetics and interoperability concerns relevant to initiatives such as the Pan-Canadian Health Data Strategy, and considers legal precedents from cases before the Federal Court of Canada and the Supreme Court of Canada. The board's expedited, full-board, and delegated review pathways mirror approaches used by the National Institutes of Health, Wellcome Trust, and the Bill & Melinda Gates Foundation's ethics panels, and address emerging issues tied to projects from groups such as Canadian HIV Trials Network, Precision Medicine Initiative, and consortia like Canada's Digital Technology Supercluster.

Impact and Controversies

The board's decisions have influenced major studies funded through partnerships with organizations like CIHR Institute of Neurosciences, Heart and Stroke Foundation of Canada, and Cancer Research UK affiliates, and affected collaborations involving multinational partners such as Pfizer, GlaxoSmithKline, and Novartis. Controversies have arisen in contexts similar to disputes seen at Boston Children's Hospital and inquiries like the Alderson Report, involving debates over consent models invoked in projects related to indigenous health research, genomic initiatives like International HapMap Project, and trials resembling historical episodes at the Hôpital Sainte-Justine. Critiques have been voiced by stakeholders including the Canadian Civil Liberties Association, provincial privacy commissioners, and health researchers from institutions like Queen's University and University of Calgary, prompting policy revisions in line with recommendations from panels convened by entities such as the Royal Society and the Council of Canadian Academies.

Category:Health research ethics committees in Canada